Industry

Best practices for meibomian gland dysfunction, part 1

Healio Optometry4d ago1 min read

Recent data suggest that 85% of dry eye disease in the U.S. is partially or completely evaporative dry eye.This means that 85% of dry eye disease (DED) likely originates in the meibomian glands of affected patients. Now is as good a time as any to review best practices for evaluating and treating meibomian gland dysfunction (MGD).But first we should look at the proper way to arrive at whatever we might call “best practices.”In a recent post on my “new look” Healio blog, I offered some thoughts on what “real” science might be. We live in an era in which there is a seemingly overwhelming urge

Read full article on Healio Optometry

AI Summary

Quick Take

Recent data indicates that 85% of dry eye disease (DED) in the United States is partially or entirely evaporative, identifying the meibomian glands as the primary source of pathology for the vast majority of patients. This high prevalence underscores the urgent need for clinicians to adopt standardized, evidence-based best practices for evaluating and treating meibomian gland dysfunction (MGD).

Why It Matters

The shift in understanding DED from a general tear deficiency to a predominantly evaporative issue changes the clinical priority from simple lubrication to targeted glandular health. As the market for dry eye treatments expands, distinguishing between 'real' science and marketing-driven protocols is essential for effective patient outcomes. For the modern eye care professional, mastering MGD management is no longer a sub-specialty but a fundamental requirement for primary ocular surface care.

Key Findings

Approximately 85% of dry eye disease cases in the U.S. are classified as partially or completely evaporative.
The meibomian glands are the likely point of origin for the vast majority of patients presenting with DED symptoms.
Effective management of DED requires a rigorous re-evaluation of current clinical protocols to ensure they align with scientifically sound 'best practices' for MGD.

Practice Implications

Given that nearly 9 out of 10 dry eye patients have a meibomian gland component, clinicians should perform a glandular evaluation on every patient reporting ocular surface discomfort. Treatment plans must move beyond palliative artificial tears to address the underlying obstruction or dysfunction of the meibomian glands to achieve long-term stability.

Who's Affected

OptometristsOphthalmologistsCornea SpecialistsDry Eye Clinic Directors

What's Next

This report marks the beginning of a series focused on establishing MGD best practices; future installments are expected to detail specific diagnostic methodologies and evidence-based treatment algorithms.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.